A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor

• Sponsor: Massachusetts General Hospital (Other)
• Overall Status: Completed
• CT.gov ID: NCT02750215
• Collaborator: Novartis (Industry)
• Enrollment: 20
• Location: 1
• Arm: 1
• Duration (Months): 60
• Patients Per Site Per Month: 0.3

Study Details

Study Description

Brief Summary

This research study is studying capmatinib as a treatment for advanced non-small cell lung cancer with MET exon 14 skipping, where the participant has already received prior therapy with a MET inhibitor.

Condition or Disease	Intervention/Treatment	Phase
Malignant Non-small Cell Neoplasm of Lung Stage IV	Drug: Capmatinib (INC280)	Phase 2

Detailed Description

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

The FDA (the U.S. Food and Drug Administration) has not approved Capmatinib as a treatment for any disease.

In this research study, the investigators are using the study drug called Capmatinib. Capmatinib is a specific blocker of the cMET protein. This protein acts as a trigger to start a series of events in your cells in what is known as the C-Met pathway. Patients with MET exon 14 skipping have activation of the MET pathway. By blocking MET, Capmatinib may slow or stop the growth and/or survival of cancer cells. Capmatinib is not yet FDA approved for the treatment of people with this type of cancer. It is not known if capmatinib will be effective in people who have previously had other drugs that block the cMET pathway. This study will help us understand how capmatinib works in the body and what capmatinib does to cancer. Any potential harmful effects of capmatinib will also be studied.

Study Design

• Study Type: Interventional
• Actual Enrollment: 20 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase 2 Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor
• Study Start Date: May 1, 2016
• Actual Primary Completion Date: May 1, 2021
• Actual Study Completion Date: May 1, 2021

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Capmatinib (INC280) Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib. After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles	Drug: Capmatinib (INC280); treatment with Capmatinib (INC280)

Outcome Measures

Primary Outcome Measures

1. Objective Response Rate [through study completion, an average of 14 months]

   Objective response rate (ORR) is defined as the percentage of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Complete response (CR) is the disappearance of all target lesions. Partial response (PR) is a greater than or equal to 30% decrease in the sum of the longest diameter of target lesions. ORR = CR + PR.

Secondary Outcome Measures

1. Progression Free Survival [through study completion, an average of 14 months]

   Progression-Free Survival (PFS) is defined as the time from registration to the earlier of progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

2. Disease Control Rate [12 weeks]

   Disease control rate (DCR) will be defined as the percentage of participants with complete response, partial response, and stable disease at 12 weeks by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. Complete Response (CR) is the disappearance of all target lesions. Partial Response (PR) is a greater than or equal to 30% decrease in the sum of the longest diameter of target lesions. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum diameters while on study. Progressive Disease (PD) is a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. DCR = CR + PR + SD.

3. Intracranial Response Rate [12 weeks]

   Intracranial response rate (IRR) will be calculated based on response assessments in the brain for patients with measurable CNS disease at baseline by RECIST v 1.1 criteria. IRR is defined as the percentage of patients with a confirmed intracranial complete response (CR) or partial response (CR) at week 12. CR is the disappearance of all target lesions and PR is a greater than or equal to 30% decrease in the sum of the longest diameter of target lesions. IRR = CR + PR.

4. Duration of Response [up to 6 months]

   Duration of response (DOR) will be calculated from the time of first assessment of complete response (CR) or partial response (PR) per RECIST 1.1 until the first occurrence of progressive disease (PD) or death. CR is the disappearance of all target lesions. PR is a greater than or equal to 30% decrease in the sum of the longest diameter of target lesions. PD is a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.

5. Overall Survival [From date of registration through study completion, an average of 14 months]

   Overall Survival (OS) is defined as the time from registration to death due to any cause, or censored at date last known alive. OS time for patients who are alive at the end of the study or are lost to follow up will be censored at the time of last contact. OS will be estimated using the Kaplan-Meier method.

6. Number of Participants With Treatment-related Adverse Events by Grade [From date of treatment start through study completion, an average of 14 months]

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years and Older
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

• Written informed consent must be obtained prior to any screening procedures.

• Age ≥ 18 years

• Histologically or cytologically confirmed non-small cell lung cancer, advanced, recurrent, or metastatic

• MET exon 14 skipping alteration by molecular testing (local testing is accepted for eligibility; all patients will have confirmation by NGS-rearrangement assay at MGH but this result is not necessary for eligibility; local molecular pathology result will suffice). This testing can be from any archival or fresh sample.

• Must have received prior platinum containing chemotherapy for advanced/metastatic non-small cell lung cancer, or have refused or be ineligible for such therapy. Prior neoadjuvant/adjuvant platinum containing chemotherapy will count has having received prior platinum, provided that disease recurred within 6 months of completion of neoadjuvant/adjuvant therapy.

• EGFR and ALK status must be known in all patients with adenocarcinoma histology. Patients with activating EGFR mutations or ALK translocations are excluded from this study, unless disease has progressed on all available, approved therapies targeting these alterations.

• At least one measurable lesion as defined by RECIST 1.1. A previously irradiated site lesion may only be counted as a target lesion if there is clear sign of progression since the irradiation.

• Must have received prior MET inhibitor as their immediately preceding therapy. There are no limits to the number of lines of prior therapy as long as prior MET inhibitor is the most recent therapy.

• Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 (CTCAE v 4.03). Patients with any grade of alopecia are allowed to enter the study.

• Patients must have adequate organ function including the following laboratory values at the screening visit:

• Absolute neutrophil count (ANC) ≥ 1.5 x 109/L without growth factor support

• Platelets ≥ 75 x 109/L

• Hemoglobin (Hgb) > 9 g/dL

• Calculated creatinine clearance (using Cockcroft-Gault formula) > 45 mL/min

• Total bilirubin ≤ 1.5 x ULN, except for patients with Gilbert's syndrome, who may only be included if total bilirubin ≤ 3.0 x ULN or direct bilirubin ≤ 1.5 x ULN

• Aspartate transaminase (AST) ≤ 3 x ULN, except for patients with liver metastasis, who are included if AST ≤ 5 x ULN

• Alanine transaminase (ALT) ≤ 3 x ULN, except for patients with liver metastasis, who are only included if ALT ≤ 5 x ULN

• Alkaline phosphatase (ALP) ≤ 5.0 x ULN

• Asymptomatic serum amylase ≤ grade 2. Patients with grade 1 or grade 2 serum amylase at the beginning of the study must be confirmed to have no signs and/or symptoms suggesting pancreatitis or pancreatic injury (e.g., elevated P-amylase, abnormal imaging findings of pancreas, etc.)

• Serum lipase ≤ ULN

• Patients must have the following laboratory values within the laboratory normal limits or corrected to within normal limits with supplements during screening:

• Potassium

• Magnesium

• Phosphorus

• Total calcium (corrected for serum albumin)

• ECOG performance status (PS) of 0 or 1

• Willing and able to comply with scheduled visits, treatment plan and laboratory tests.

Exclusion Criteria:

• Patients with known hypersensitivity to any of the excipients of INC280 (crospovidone, mannitol, microcrystalline cellulose, povidone, sodium lauryl sulfate, magnesium stearate, colloidal silicon dioxide, and various coating premixes).

• Patients with symptomatic central nervous system (CNS) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage CNS symptoms

• Presence or history of carcinomatous meningitis

• Presence or history of a malignant disease other than disease to be treated in current protocol that has been diagnosed and/or required therapy within the past 3 years. Exceptions to this exclusion include the following: completely resected basal cell and squamous cell skin cancers, indolent malignancies that currently do not require treatment, and completely resected carcinoma in situ of any type

• Clinically significant, uncontrolled heart diseases.

• Unstable angina within 6 months prior to screening

• Myocardial infarction within 6 months prior to screening

• History of documented congestive heart failure (New York Heart Association functional classification III-IV)

• Uncontrolled hypertension defined by a Systolic Blood Pressure (SBP) ≥ 160 mm Hg and/or Diastolic Blood Pressure (DBP) ≥ 100 mm Hg, with or without antihypertensive medication. Initiation or adjustment of antihypertensive medication (s) is allowed prior to screening

• Ventricular arrhythmias

• Supraventricular and nodal arrhythmias not controlled with medication

• Other cardiac arrhythmia not controlled with medication

• QTcF > 480 msec

• Thoracic radiotherapy to lung fields ≤ 4 weeks prior to starting INC280 or patients who have not recovered from radiotherapy-related toxicities. For all other anatomic sites (including radiotherapy to thoracic vertebrae and ribs), radiotherapy ≤ 2 weeks prior to starting INC280 or patients who have not recovered from radiotherapy-related toxicities. Palliative radiotherapy for bone lesions ≤ 2 weeks prior to starting INC280 is allowed

• Major surgery (e.g., intra-thoracic, intra-abdominal or intra-pelvic) within 4 weeks prior (2 weeks for resection of brain metastases) to starting INC280 or who have not recovered from side effects of such procedure. Video-assisted thoracic surgery (VATS) and mediastinoscopy will not be counted as major surgery and patients can be enrolled in the study ≥ 1 week after the procedure

• Patients receiving treatment with medications that meet one of the following criteria and that cannot be discontinued at least 1 week prior to the start of treatment with

INC280 and for the duration of the study:

• Strong and moderate inhibitors of CYP3A4

• Strong inducers of CYP3A4

• Proton pump inhibitors (PPI)

• Impairment of GI function or GI disease that may significantly alter the absorption of INC280 (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, or malabsorption syndrome)

• Unable or unwilling to swallow tablets as per dosing schedule

• Patients receiving unstable or increasing doses of corticosteroids. If patients are on corticosteroids for endocrine deficiencies or tumor-associated symptoms other than CNS related, dose must have been stabilized (or decreasing) for at least 5 days before first dose of INC280

• Patients receiving treatment with any enzyme-inducing anticonvulsant that cannot be discontinued at least 1 week before first dose of INC280, and for the duration of the study. Patients on non-enzyme-inducing anticonvulsants are eligible

• Previous anti-cancer and investigational agents within 4 weeks or ≤ 5 x half-life of the agent (whichever is longer) before first dose of INC280. If previous treatment is a monoclonal antibody, then the treatment must be discontinued at least 4 weeks before first dose of INC280

• Other severe, acute, or chronic medical or psychiatric conditions or laboratory abnormalities that in the opinion of the investigator may increase the risk associated with study participation, or that may interfere with the interpretation of study results

• Any other condition that would, in the Investigator's judgment, contraindicate patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures, e.g., infection/inflammation, intestinal obstruction, unable to swallow medication, social/ psychological issues, etc.

• Pregnant or nursing women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test

• Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing and for 7 days after stopping treatment. Highly effective contraception methods include:

• Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception

• Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment

• Male sterilization (at least 6 months prior to screening). For female subjects on the study the vasectomized male partner should be the sole partner for that subject

• Combination of any two of the following (a+b or a+c, or b+c):

• Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate ≤ 1%), for example hormone vaginal ring or transdermal hormone contraception

• Placement of an intrauterine device (IUD) or intrauterine system (IUS)

• Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository

• In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment.

• Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g., age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential

• Sexually active males unless they use a condom during intercourse while taking drug and for 7 days after stopping treatment and should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Massachusetts General Hospital	Boston	Massachusetts	United States	02114

Sponsors and Collaborators

• Massachusetts General Hospital
• Novartis

Investigators

• Principal Investigator: Rebecca S. Heist, MD, Massachusetts General Hospital

Study Documents (Full-Text)

• Study Protocol and Statistical Analysis Plan - Aug 6, 2019
• Informed Consent Form - Feb 6, 2020

More Information

Publications

None provided.

• Responsible Party: Rebecca Suk Heist, MD, Principal Investigator, Massachusetts General Hospital
• ClinicalTrials.gov Identifier: NCT02750215
• Other Study ID Numbers: 16-019
• First Posted: Apr 25, 2016
• Last Update Posted: Mar 14, 2022
• Last Verified: Mar 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Keywords provided by Rebecca Suk Heist, MD, Principal Investigator, Massachusetts General Hospital: MET exon 14 skipping; Stage IV non-small cell lung cancer NSCLC
• Additional relevant MeSH terms: Lung Neoplasms

Study Results

Participant Flow

Arm/Group Title	Capmatinib (INC280)
Arm/Group Description	Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib. After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles Capmatinib (INC280): treatment with Capmatinib (INC280)
Period Title: Overall Study
STARTED	20
COMPLETED	20
NOT COMPLETED	0

Baseline Characteristics

Arm/Group Title	Capmatinib (INC280)
Arm/Group Description	Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib. After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles Capmatinib (INC280): treatment with Capmatinib (INC280)
Overall Participants	20
Age, Customized (years) [Median (Full Range) ]
Age	70
Sex: Female, Male (Count of Participants)
Female	12 60%
Male	8 40%
Race (NIH/OMB) (Count of Participants)
American Indian or Alaska Native	0 0%
Asian	1 5%
Native Hawaiian or Other Pacific Islander	0 0%
Black or African American	0 0%
White	18 90%
More than one race	0 0%
Unknown or Not Reported	1 5%
Smoking History (participants) [Number]
Never	8 40%
Former	11 55%
Current	1 5%
Tumor Histology (participants) [Number]
Adenocarcinoma	16 80%
Squamous	2 10%
Sarcomatoid or poorly differentiated carcinoma	2 10%
MET alteration (participants) [Number]
Amplification	5 25%
Exon 14 skipping	15 75%
Previous Chemotherapy (participants) [Number]
Yes	11 55%
No	9 45%
Previous Immunotherapy (participants) [Number]
Yes	7 35%
No	13 65%
Number of previous lines of therapy (participants) [Number]
1	9 45%
2	3 15%
3 or more	8 40%
Number of previous MET-targeted therapies (participants) [Number]
1	17 85%
2	3 15%

Outcome Measures

1. Primary Outcome

Title	Objective Response Rate
Description	Objective response rate (ORR) is defined as the percentage of patients with a complete response or partial response to treatment according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Complete response (CR) is the disappearance of all target lesions. Partial response (PR) is a greater than or equal to 30% decrease in the sum of the longest diameter of target lesions. ORR = CR + PR.
Time Frame	through study completion, an average of 14 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Capmatinib (INC280)
Arm/Group Description	Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib. After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles Capmatinib (INC280): treatment with Capmatinib (INC280)
Measure Participants	20
Number [percentage of participants]	10 50%

2. Secondary Outcome

Title	Progression Free Survival
Description	Progression-Free Survival (PFS) is defined as the time from registration to the earlier of progression or death due to any cause. Participants alive without disease progression are censored at date of last disease evaluation. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time Frame	through study completion, an average of 14 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Capmatinib (INC280)
Arm/Group Description	Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib. After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles Capmatinib (INC280): treatment with Capmatinib (INC280)
Measure Participants	20
Median (95% Confidence Interval) [months]	5.5

3. Secondary Outcome

Title	Disease Control Rate
Description	Disease control rate (DCR) will be defined as the percentage of participants with complete response, partial response, and stable disease at 12 weeks by Response Evaluation Criteria In Solid Tumors (RECIST) v1.1. Complete Response (CR) is the disappearance of all target lesions. Partial Response (PR) is a greater than or equal to 30% decrease in the sum of the longest diameter of target lesions. Stable Disease (SD) is neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for Progressive Disease, taking as reference the smallest sum diameters while on study. Progressive Disease (PD) is a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. DCR = CR + PR + SD.
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Capmatinib (INC280)
Arm/Group Description	Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib. After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles Capmatinib (INC280): treatment with Capmatinib (INC280)
Measure Participants	20
Number [percentage of participants]	80 400%

4. Secondary Outcome

Title	Intracranial Response Rate
Description	Intracranial response rate (IRR) will be calculated based on response assessments in the brain for patients with measurable CNS disease at baseline by RECIST v 1.1 criteria. IRR is defined as the percentage of patients with a confirmed intracranial complete response (CR) or partial response (CR) at week 12. CR is the disappearance of all target lesions and PR is a greater than or equal to 30% decrease in the sum of the longest diameter of target lesions. IRR = CR + PR.
Time Frame	12 weeks

Outcome Measure Data

Analysis Population Description

Only 4 out of 20 participants had measurable brain metastases.

Arm/Group Title	Capmatinib (INC280)
Arm/Group Description	Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib. After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles Capmatinib (INC280): treatment with Capmatinib (INC280)
Measure Participants	4
Number [percentage of participants]	0 0%

5. Secondary Outcome

Title	Duration of Response
Description	Duration of response (DOR) will be calculated from the time of first assessment of complete response (CR) or partial response (PR) per RECIST 1.1 until the first occurrence of progressive disease (PD) or death. CR is the disappearance of all target lesions. PR is a greater than or equal to 30% decrease in the sum of the longest diameter of target lesions. PD is a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.
Time Frame	up to 6 months

Outcome Measure Data

Analysis Population Description

Only 2 of 22 participants had complete response (CR) or partial response (PR) per RECIST 1.1, thus they were the only ones analyzed for DOR.

Arm/Group Title	Capmatinib (INC280)
Arm/Group Description	Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib. After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles Capmatinib (INC280): treatment with Capmatinib (INC280)
Measure Participants	2
Mean (Full Range) [months]	3.8

6. Secondary Outcome

Title	Overall Survival
Description	Overall Survival (OS) is defined as the time from registration to death due to any cause, or censored at date last known alive. OS time for patients who are alive at the end of the study or are lost to follow up will be censored at the time of last contact. OS will be estimated using the Kaplan-Meier method.
Time Frame	From date of registration through study completion, an average of 14 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Capmatinib (INC280)
Arm/Group Description	Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib. After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles Capmatinib (INC280): treatment with Capmatinib (INC280)
Measure Participants	20
Median (95% Confidence Interval) [months]	11.3

7. Secondary Outcome

Title	Number of Participants With Treatment-related Adverse Events by Grade
Time Frame	From date of treatment start through study completion, an average of 14 months

Outcome Measure Data

Analysis Population Description

[Not Specified]

Arm/Group Title	Capmatinib (INC280)
Arm/Group Description	Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib. After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles Capmatinib (INC280): treatment with Capmatinib (INC280)
Measure Participants	20
Grade 3	8 40%
Grade 4	0 0%
Grade 5	2 10%

Adverse Events

Time Frame	Adverse event data were collected from the treatment start date through study completion, an average of 14 months
Arm/Group Title	Capmatinib (INC280)
Arm/Group Description	Patients who fulfill eligibility criteria will be entered into the trial to receive capmatinib. After the screening procedures confirm participation in the research study. Participants will receive capmatinib PO BID, 21-day cycles Capmatinib (INC280): treatment with Capmatinib (INC280)
All Cause Mortality
	Capmatinib (INC280)
	Affected / at Risk (%)	# Events
Total	15/20 (75%)
Serious Adverse Events
	Capmatinib (INC280)
	Affected / at Risk (%)	# Events
Total	2/20 (10%)
General disorders
Edema limbs	1/20 (5%)
Injury, poisoning and procedural complications
Hip fracture	1/20 (5%)
Wound infection	1/20 (5%)
Nervous system disorders
seizure	1/20 (5%)
Stroke	1/20 (5%)
Vascular disorders
Thromboembolic event	1/20 (5%)
Other (Not Including Serious) Adverse Events
	Capmatinib (INC280)
	Affected / at Risk (%)	# Events
Total	18/20 (90%)
Cardiac disorders
Atrioventricular block first degree	1/20 (5%)
Gastrointestinal disorders
Abdominal pain	1/20 (5%)
Constipation	1/20 (5%)
Diarrhea	2/20 (10%)
Nausea	7/20 (35%)
Vomiting	2/20 (10%)
General disorders
Fatigue	7/20 (35%)
Edema limbs	13/20 (65%)
Immune system disorders
Allergic reaction	1/20 (5%)
Investigations
Serum amylase increased	4/20 (20%)
Aspartate aminotransferase increased	2/20 (10%)
Alanine aminotransferase increased	3/20 (15%)
Creatinine increased	4/20 (20%)
Blood bilirubin increased	1/20 (5%)
Lipase increased	4/20 (20%)
Platelet count decreased	1/20 (5%)
Weight gain	1/20 (5%)
Metabolism and nutrition disorders
Anorexia	1/20 (5%)
Hypocalcemia	1/20 (5%)
Hypophosphatemia	2/20 (10%)
Musculoskeletal and connective tissue disorders
myalgia	4/20 (20%)
Nervous system disorders
Dysgeusia	1/20 (5%)
Peripheral sensory neuropathy	3/20 (15%)
Reproductive system and breast disorders
Dyspnea	1/20 (5%)
Respiratory, thoracic and mediastinal disorders
Nasal congestion	1/20 (5%)
Pneumonitis	2/20 (10%)

Limitations/Caveats

[Not Specified]

More Information

Certain Agreements

All Principal Investigators ARE employed by the organization sponsoring the study.

There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.